2023 Q1 Form 10-K Financial Statement
#000114036123014526 Filed on March 29, 2023
Income Statement
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|
Balance Sheet
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $18.18M | $18.18M | |
| YoY Change | -36.82% | -36.82% | |
| Cash & Equivalents | $18.18M | $18.18M | |
| Short-Term Investments | |||
| Other Short-Term Assets | $3.835M | $3.835M | |
| YoY Change | 82.91% | 82.91% | |
| Inventory | $7.715M | $7.715M | |
| Prepaid Expenses | |||
| Receivables | $6.536M | $6.536M | |
| Other Receivables | $12.19M | $12.19M | |
| Total Short-Term Assets | $48.45M | $48.45M | |
| YoY Change | -12.27% | -12.27% | |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $8.155M | $13.72M | |
| YoY Change | -4.7% | -6.25% | |
| Goodwill | $0.00 | ||
| YoY Change | -100.0% | ||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $434.9K | $434.9K | |
| YoY Change | 21.47% | 21.47% | |
| Total Long-Term Assets | $14.16M | $14.16M | |
| YoY Change | -21.43% | -21.43% | |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $48.45M | $48.45M | |
| Total Long-Term Assets | $14.16M | $14.16M | |
| Total Assets | $62.61M | $62.61M | |
| YoY Change | -14.53% | -14.53% | |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.343M | $3.343M | |
| YoY Change | -56.84% | -56.84% | |
| Accrued Expenses | $17.30M | $17.30M | |
| YoY Change | 176.02% | 176.02% | |
| Deferred Revenue | $0.00 | ||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | |
| YoY Change | |||
| Long-Term Debt Due | $18.58M | $18.65M | |
| YoY Change | 1448.14% | 1370.97% | |
| Total Short-Term Liabilities | $39.30M | $39.30M | |
| YoY Change | 157.16% | 157.16% | |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $86.90K | $86.90K | |
| YoY Change | -99.51% | -99.51% | |
| Other Long-Term Liabilities | $5.426M | $5.426M | |
| YoY Change | -9.21% | -9.21% | |
| Total Long-Term Liabilities | $5.513M | $5.513M | |
| YoY Change | -76.74% | -76.74% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $39.30M | $39.30M | |
| Total Long-Term Liabilities | $5.513M | $5.513M | |
| Total Liabilities | $44.81M | $44.81M | |
| YoY Change | 14.94% | 14.94% | |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$154.3M | ||
| YoY Change | 17.78% | ||
| Common Stock | $367.7K | ||
| YoY Change | 22.13% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $206.6K | ||
| YoY Change | 0.0% | ||
| Treasury Stock Shares | $48.06K | ||
| Shareholders Equity | $17.80M | $17.80M | |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $62.61M | $62.61M | |
| YoY Change | -14.53% | -14.53% |
Cashflow Statement
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28772892 | |
| CY2022Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
136976 | |
| CY2021Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
191870 | |
| CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5433211 | |
| CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5891906 | |
| CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
0 | |
| CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
3022787 | |
| CY2022Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
434872 | |
| CY2021Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
358010 | |
| CY2022Q4 | us-gaap |
Assets
Assets
|
62611405 | |
| CY2021Q4 | us-gaap |
Assets
Assets
|
73252195 | |
| CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
19730697 | |
| CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
13127993 | |
| CY2022Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
18577693 | |
| CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
914857 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
886294 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
76869 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
68176 | |
| CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
39300116 | |
| CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
15282463 | |
| CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
5426030 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
5976151 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
76705 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
139678 | |
| CY2022Q4 | us-gaap |
Long Term Line Of Credit
LongTermLineOfCredit
|
10197 | |
| CY2021Q4 | us-gaap |
Long Term Line Of Credit
LongTermLineOfCredit
|
17589003 | |
| CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
44813048 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36765785 | |
| CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36765785 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30104986 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
30104986 | |
| CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
367658 | |
| CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
301050 | |
| CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
172275057 | |
| CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
165772636 | |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-131009860 | |
| CY2022Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
48057 | |
| CY2021Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
48057 | |
| CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-501456 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33903529 | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
34264900 | |
| CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
47818452 | |
| CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7067852 | |
| CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12487424 | |
| CY2022 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
24277834 | |
| CY2021 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
24840611 | |
| CY2022 | us-gaap |
Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
|
3236186 | |
| CY2021 | us-gaap |
Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
|
7047779 | |
| CY2021 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-2912415 | |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-23256252 | |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-33965579 | |
| CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
34405 | |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-62050 | |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23290657 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33903529 | |
| CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.72 | |
| CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.72 | |
| CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.4 | |
| CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.4 | |
| CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
32269147 | |
| CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
32269147 | |
| CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
24299465 | |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23290657 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33903529 | |
| CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
255085 | |
| CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-501456 | |
| CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-23035572 | |
| CY2021 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-34404985 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
27776409 | |
| CY2021 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
38811958 | |
| CY2021 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
106941 | |
| CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
1160953 | |
| CY2021 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
145225 | |
| CY2021 | us-gaap |
Treasury Stock Value Acquired Par Value Method
TreasuryStockValueAcquiredParValueMethod
|
0 | |
| CY2022 | us-gaap |
Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
|
63624525 | |
| CY2021 | us-gaap |
Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
|
65273967 | |
| CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1453778 | |
| CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1404532 | |
| CY2022 | cemi |
Operating Cash Flows From Finance Leases
OperatingCashFlowsFromFinanceLeases
|
17015 | |
| CY2021 | cemi |
Operating Cash Flows From Finance Leases
OperatingCashFlowsFromFinanceLeases
|
20077 | |
| CY2022 | cemi |
Interest And Tax Expense Net
InterestAndTaxExpenseNet
|
-2129104 | |
| CY2021 | cemi |
Interest And Tax Expense Net
InterestAndTaxExpenseNet
|
-2281124 | |
| CY2022 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
266087 | |
| CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
967262 | |
| CY2022 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
41537 | |
| CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
0 | |
| CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1065731 | |
| CY2022 | us-gaap |
Treasury Stock Value Acquired Par Value Method
TreasuryStockValueAcquiredParValueMethod
|
0 | |
| CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
255085 | |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23290657 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-30885716 | |
| CY2022 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
70514 | |
| CY2021 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
61867 | |
| CY2022 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
900000 | |
| CY2021 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | |
| CY2022 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
41537 | |
| CY2021 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
145225 | |
| CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3367253 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
38690421 | |
| CY2022 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
184026 | |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
28772892 | |
| CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23290657 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-33903529 | |
| CY2022 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2552969 | |
| CY2021 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2930976 | |
| CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2299081 | |
| CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2431982 | |
| CY2022 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| CY2021 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-69941 | |
| CY2022 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
103854 | |
| CY2021 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
-53751 | |
| CY2022 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
569430 | |
| CY2021 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
4054701 | |
| CY2021 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
5880741 | |
| CY2022 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-4800838 | |
| CY2021 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
8009969 | |
| CY2022 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-4635608 | |
| CY2021 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
4458750 | |
| CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2124366 | |
| CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
545305 | |
| CY2022 | us-gaap |
Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
|
76862 | |
| CY2021 | us-gaap |
Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
|
234874 | |
| CY2022 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
6602704 | |
| CY2021 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
3085205 | |
| CY2022 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
0 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-30885716 | |
| CY2022 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 1 — DESCRIPTION OF BUSINESS:</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Chembio Diagnostics, Inc. (“Chembio”) and its subsidiaries (collectively with Chembio, the “Company”) develop and commercialize point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment.</div> <div style="font-weight: normal;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company’s</span> </span>product portfolio is based upon our proprietary DPP technology, a diagnostic platform that provides high-quality, cost-effective results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections and HIV, and Women<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">’</span></span>s Health. Compared with traditional lateral flow technology, the DPP technology platform can provide:</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; align: right;"> <div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Enhanced sensitivity and specificity: This is achieved via the Company’s proprietary approach to separating the sample path from the buffer path, together with patent and other proprietary strategies, which differ significantly from traditional lateral flow test.</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; align: right;"> <div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Advanced multiplexing capabilities: Through advanced multiplexing, the DPP platform can detect and differentiate up to eight distinct test results from a single patient sample, which can deliver greater clinical value than other rapid tests currently on the market.</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; align: right;"> <div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Objective results: For some diagnostic applications, the Company’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzers can report accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on site. Objective results produced by the DPP Micro Reader can reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.</div> </td> </tr> </table> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">The Company targets the market for rapid diagnostic test solutions for infectious diseases, which is driven by the high prevalence of infectious diseases globally, an increase in the geriatric population, growing demand for rapid test results, and advancements in multiplexing. The Company has a broad portfolio of infectious disease products, which prior to 2020 were focused principally on sexually transmitted disease and fever and tropical disease. In February 2020 the Company began the process to leverage the DPP technology platform to address the acute and escalating need for diagnostic testing. The Company is continuing to pursue or has pursued:</div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; align: right;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">•</div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">a 510(k) clearance from the U. S. Food and Drug Administration (the “FDA”) for the DPP SARS-CoV-2 Antigen test system;</div> </td> </tr> </table> <div> <br/> </div> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; align: right;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">•</div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">an Emergency Use Authorization from the FDA for the DPP Respiratory Antigen Panel; and</div> </td> </tr> </table> <div> <br/> </div> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; align: right;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">a Clinical Laboratory Improvement Amendment (“CLIA”), waiver from the FDA for the DPP HIV-Syphilis test system, which was approved in February 2023.</span><br/> </div> </td> </tr> </table> </div> | |
| CY2022 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | |
| CY2021 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
3300000 | |
| CY2022 | cemi |
Term Over Which Revenue Will Be Recognized
TermOverWhichRevenueWillBeRecognized
|
P1Y | |
| CY2022Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
0 | |
| CY2021 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
4100000 | |
| CY2022 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2022 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
| CY2022 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2022 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001092662 | |
| CY2022 | us-gaap |
Impairment Of Intangible Asset Indefinite Lived Excluding Goodwill Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
|
http://fasb.org/us-gaap/2022#RestructuringCostsAndAssetImpairmentCharges | |
| CY2021 | us-gaap |
Impairment Of Intangible Asset Indefinite Lived Excluding Goodwill Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
|
http://fasb.org/us-gaap/2022#RestructuringCostsAndAssetImpairmentCharges | |
| CY2022 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2022 | cemi |
Minimum Bid Price Requirement Threshold Consecutive Business Days
MinimumBidPriceRequirementThresholdConsecutiveBusinessDays
|
P10D | |
| CY2022 | dei |
Auditor Firm
AuditorFirmId
|
42 | |
| CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2022 | dei |
Document Type
DocumentType
|
10-K | |
| CY2022 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
| CY2022 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-12-31 | |
| CY2022 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2022 | dei |
Entity File Number
EntityFileNumber
|
001-35569 | |
| CY2022 | dei |
Entity Registrant Name
EntityRegistrantName
|
CHEMBIO DIAGNOSTICS, INC. | |
| CY2022 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
| CY2022 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
88-0425691 | |
| CY2022 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
3661 Horseblock Rd | |
| CY2022 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Medford | |
| CY2022 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NY | |
| CY2022 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
11763 | |
| CY2022 | dei |
City Area Code
CityAreaCode
|
631 | |
| CY2022 | dei |
Local Phone Number
LocalPhoneNumber
|
924-1135 | |
| CY2022 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.01 par value | |
| CY2022 | dei |
Trading Symbol
TradingSymbol
|
CEMI | |
| CY2022 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2022 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2022 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2022 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2022 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2022 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2022 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2022 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2022 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2022 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
true | |
| CY2022 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2022Q2 | dei |
Entity Public Float
EntityPublicFloat
|
18739117 | |
| CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
36725858 | |
| CY2022 | dei |
Auditor Name
AuditorName
|
Ernst & Young LLP | |
| CY2022 | dei |
Auditor Location
AuditorLocation
|
Jericho, New York | |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18178985 | |
| CY2022Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
346896 | |
| CY2021Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
243042 | |
| CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
6536415 | |
| CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
11441107 | |
| CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
7715413 | |
| CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
12920451 | |
| CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3834560 | |
| CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1710194 | |
| CY2022Q4 | us-gaap |
Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
|
12186322 | |
| CY2021Q4 | us-gaap |
Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
|
0 | |
| CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
48451695 | |
| CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
54844644 | |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8154651 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8556773 | |
| CY2022Q4 | us-gaap |
Insurance Settlements Receivable Noncurrent
InsuranceSettlementsReceivableNoncurrent
|
0 | |
| CY2021Q4 | us-gaap |
Insurance Settlements Receivable Noncurrent
InsuranceSettlementsReceivableNoncurrent
|
386205 | |
| CY2021Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
1200000 | |
| CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
38987295 | |
| CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-154300517 | |
| CY2022Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
206554 | |
| CY2021Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
206554 | |
| CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-337287 | |
| CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-592372 | |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
17798357 | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
34264900 | |
| CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
62611405 | |
| CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
73252195 | |
| CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
49521923 | |
| CY2022 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
38578098 | |
| CY2021 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
34495802 | |
| CY2022 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
73159970 | |
| CY2021 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
78871616 | |
| CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-23638047 | |
| CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-31053164 | |
| CY2022 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-2812772 | |
| CY2022 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
3194567 | |
| CY2021 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
0 | |
| CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24299465 | |
| CY2021 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
85555 | |
| CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
873294 | |
| CY2021 | cemi |
Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
|
0 | |
| CY2022 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4311486 | |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
17798357 | |
| CY2022 | us-gaap |
Proceeds From Customers
ProceedsFromCustomers
|
53886080 | |
| CY2021 | us-gaap |
Proceeds From Customers
ProceedsFromCustomers
|
37232082 | |
| CY2022 | cemi |
Cash Received From Insurance Receivable
CashReceivedFromInsuranceReceivable
|
644389 | |
| CY2021 | cemi |
Cash Received From Insurance Receivable
CashReceivedFromInsuranceReceivable
|
861902 | |
| CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12693953 | |
| CY2022 | cemi |
Payments For Proceeds From Acquisition Of And Deposits On Fixed Assets
PaymentsForProceedsFromAcquisitionOfAndDepositsOnFixedAssets
|
1451233 | |
| CY2021 | cemi |
Payments For Proceeds From Acquisition Of And Deposits On Fixed Assets
PaymentsForProceedsFromAcquisitionOfAndDepositsOnFixedAssets
|
1824285 | |
| CY2022 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | |
| CY2021 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
33398 | |
| CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1451233 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1857683 | |
| CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4311486 | |
| CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
38811958 | |
| CY2022 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | |
| CY2021 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
85555 | |
| CY2022 | cemi |
Proceeds From Interest Received On Employee Retention Credit
ProceedsFromInterestReceivedOnEmployeeRetentionCredit
|
67818 | |
| CY2021 | cemi |
Proceeds From Interest Received On Employee Retention Credit
ProceedsFromInterestReceivedOnEmployeeRetentionCredit
|
0 | |
| CY2021 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-240431 | |
| CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-10593907 | |
| CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
5706591 | |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
28772892 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
23066301 | |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
18178985 | |
| CY2022 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
3033565 | |
| CY2022 | cemi |
Increase Decrease In Insurance Settlements Receivable Current
IncreaseDecreaseInInsuranceSettlementsReceivableCurrent
|
12186322 | |
| CY2021 | cemi |
Increase Decrease In Insurance Settlements Receivable Current
IncreaseDecreaseInInsuranceSettlementsReceivableCurrent
|
0 | |
| CY2022 | cemi |
Increase Decrease In Insurance Settlements Receivable Non Current
IncreaseDecreaseInInsuranceSettlementsReceivableNonCurrent
|
-386205 | |
| CY2021 | cemi |
Increase Decrease In Insurance Settlements Receivable Non Current
IncreaseDecreaseInInsuranceSettlementsReceivableNonCurrent
|
386205 | |
| CY2021 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1606997 | |
| CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12693953 | |
| CY2022 | cemi |
Line Of Credit Facility Covenant Minimum Cash Balance
LineOfCreditFacilityCovenantMinimumCashBalance
|
3000000 | |
| CY2022 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-style: italic;">(b)</span> <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Use of Estimates:</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make assumptions and estimates that affect the amounts reported in the consolidated financial statements and accompanying notes. Judgments and estimates of uncertainties are required in applying the Company’s accounting policies in certain areas. Generally, matters subject to estimation and judgment include accounts receivable realization, inventory obsolescence, asset impairments, recognition of revenue, useful lives of fixed assets, stock-based compensation, insurance recoveries, and deferred tax asset valuation allowances. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from those estimates.</div> | |
| CY2022 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-style: italic;">(e)</span> <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Concentrations of Credit Risk:</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and trade receivables. The Company places its cash with well-known financial institutions and, at times, may maintain balances in excess of the FDIC insurance limit.</div> | |
| CY2021Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
0 | |
| CY2022 | us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
1 | |
| CY2022 | us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
3000000 | |
| CY2021 | us-gaap |
Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
|
2600000 | |
| CY2022 | cemi |
Percentage Of Minimum Lease Payment For Fair Value
PercentageOfMinimumLeasePaymentForFairValue
|
0.90 | |
| CY2022Q4 | us-gaap |
Lessee Finance Lease Remaining Lease Term
LesseeFinanceLeaseRemainingLeaseTerm
|
P12M | |
| CY2021Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
494258 | |
| CY2022Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
400409 | |
| CY2021Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
421416 | |
| CY2022Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
1467756 | |
| CY2021Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
1378706 | |
| CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
114000 | |
| CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
122935 | |
| CY2022Q4 | cemi |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
11182997 | |
| CY2021Q4 | cemi |
Accrued Legal Fees Current
AccruedLegalFeesCurrent
|
400000 | |
| CY2022Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
4539346 | |
| CY2021Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
7306095 | |
| CY2022Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1106962 | |
| CY2021Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
3556878 | |
| CY2022Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2069105 | |
| CY2021Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2057478 | |
| CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
7715413 | |
| CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
12920451 | |
| CY2022 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
600000 | |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
20310055 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
18858822 | |
| CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
12155404 | |
| CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
10302049 | |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8154651 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8556773 | |
| CY2022 | us-gaap |
Depreciation
Depreciation
|
1900000 | |
| CY2021 | us-gaap |
Depreciation
Depreciation
|
1800000 | |
| CY2022Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
3342926 | |
| CY2021Q4 | us-gaap |
Accounts Payable Trade Current
AccountsPayableTradeCurrent
|
7745592 | |
| CY2022Q4 | cemi |
Accrued Sales Commission And Royalties Current
AccruedSalesCommissionAndRoyaltiesCurrent
|
2425302 | |
| CY2021Q4 | cemi |
Accrued Sales Commission And Royalties Current
AccruedSalesCommissionAndRoyaltiesCurrent
|
1359691 | |
| CY2022Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
330784 | |
| CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
466523 | |
| CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1205395 | |
| CY2022Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
19730697 | |
| CY2021Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
13127993 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
49521923 | |
| CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
49521923 | |
| CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
47818452 | |
| CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
47818452 | |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-18425426 | |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-26858325 | |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-4830826 | |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-7107254 | |
| CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-23256252 | |
| CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-33965579 | |
| CY2022 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | |
| CY2021 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | |
| CY2022 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
33948 | |
| CY2021 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
7891 | |
| CY2022 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
457 | |
| CY2021 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
0 | |
| CY2022 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
34405 | |
| CY2021 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
7891 | |
| CY2022 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | |
| CY2021 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
0 | |
| CY2022 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
0 | |
| CY2021 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
0 | |
| CY2022 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
0 | |
| CY2021 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
-69941 | |
| CY2022 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | |
| CY2021 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-69941 | |
| CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
34405 | |
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-62050 | |
| CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
1407504 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0001 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0018 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
-0.0369 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
|
-0.0204 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.004 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.0032 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.1685 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.196 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.0102 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.0032 | |
| CY2022 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.0015 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.0018 | |
| CY2003Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
5832516 | |
| CY2003 | cemi |
Annual Limitation
AnnualLimitation
|
150608 | |
| CY2003 | cemi |
Operating Loss Carryforward Built In Gains
OperatingLossCarryforwardBuiltInGains
|
488207 | |
| CY2005Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
8586861 | |
| cemi |
Annual Limitation
AnnualLimitation
|
1111831 | ||
| cemi |
Operating Loss Carryforward Built In Gains
OperatingLossCarryforwardBuiltInGains
|
1756842 | ||
| CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
|
25671216 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
|
66924161 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1632846 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
|
343262 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
|
333551 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
822145 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
374673 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
22123522 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
20401828 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1632846 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1651529 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
628711 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
0 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
437992 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
259106 | |
| CY2022Q4 | us-gaap |
Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
|
1825347 | |
| CY2021Q4 | us-gaap |
Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
|
1221171 | |
| CY2022Q4 | cemi |
Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
|
1381089 | |
| CY2021Q4 | cemi |
Deferred Tax Assets Lease Obligations
DeferredTaxAssetsLeaseObligations
|
1504433 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
136478 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
137142 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
29331392 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
25883433 | |
| CY2022Q4 | cemi |
Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
|
1155407 | |
| CY2021Q4 | cemi |
Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
|
1294519 | |
| CY2022Q4 | cemi |
Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
|
252097 | |
| CY2021Q4 | cemi |
Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
|
560754 | |
| CY2021Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
1855273 | |
| CY2022Q4 | cemi |
Deferred Tax Assets Net Of Property Plant And Equipment
DeferredTaxAssetsNetOfPropertyPlantAndEquipment
|
27923888 | |
| CY2021Q4 | cemi |
Deferred Tax Assets Net Of Property Plant And Equipment
DeferredTaxAssetsNetOfPropertyPlantAndEquipment
|
24028160 | |
| CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
27923888 | |
| CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
24028160 | |
| CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
0 | |
| CY2021Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
0 | |
| CY2022Q4 | us-gaap |
Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
|
0 | |
| CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
3022787 | |
| CY2022 | us-gaap |
Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
|
10778 | |
| CY2022 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
3033565 | |
| CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
0 | |
| CY2022 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
3000000 | |
| CY2021 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
2600000 | |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
0 | |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
0 | |
| CY2022Q4 | cemi |
Finite Lived Intangible Assets Impairment
FiniteLivedIntangibleAssetsImpairment
|
0 | |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
0 | |
| CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
4946421 | |
| CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
1896290 | |
| CY2021Q4 | cemi |
Finite Lived Intangible Assets Impairment
FiniteLivedIntangibleAssetsImpairment
|
3050131 | |
| CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
0 | |
| CY2022 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | |
| CY2021 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
479988 | |
| CY2021 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
3100000 | |
| CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
0 | |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2022Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
48057 | |
| CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2299081 | |
| CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2034247 | |
| CY2022Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
3657163 | |
| CY2022 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P8Y14D | |
| CY2022Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
2.2 | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | |
| CY2022Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
581574 | |
| CY2022Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
3.98 | |
| CY2022Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | |
| CY2021Q3 | cemi |
Amount Made Available For Cash Awards
AmountMadeAvailableForCashAwards
|
1500000 | |
| CY2022 | cemi |
Payments Made By The Company
PaymentsMadeByTheCompany
|
600000 | |
| CY2021 | cemi |
Payments Made By The Company
PaymentsMadeByTheCompany
|
100000 | |
| CY2022Q4 | cemi |
Number Of Groups Of Similar Products
NumberOfGroupsOfSimilarProducts
|
1 | |
| CY2022 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8154651 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8556773 | |
| CY2022Q4 | cemi |
Number Of Key Employees With Whom Company Has Employment Contracts
NumberOfKeyEmployeesWithWhomCompanyHasEmploymentContracts
|
3 | |
| CY2022Q4 | us-gaap |
Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
|
1178000 | |
| CY2022Q4 | us-gaap |
Other Commitment Due In Second Year
OtherCommitmentDueInSecondYear
|
383000 | |
| CY2022 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.40 | |
| CY2022 | us-gaap |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
0.05 | |
| CY2022 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.02 | |
| CY2022 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
191113 | |
| CY2021 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
138513 | |
| CY2022 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1630609 | |
| CY2021 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1625280 | |
| CY2022 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
71129 | |
| CY2021 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
66872 | |
| CY2022 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
17015 | |
| CY2021 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
20077 | |
| CY2022 | cemi |
Finance Lease Cost
FinanceLeaseCost
|
88144 | |
| CY2021 | cemi |
Finance Lease Cost
FinanceLeaseCost
|
86949 | |
| CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1453778 | |
| CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1404532 | |
| CY2022 | cemi |
Operating Cash Flows From Finance Leases
OperatingCashFlowsFromFinanceLeases
|
17015 | |
| CY2021 | cemi |
Operating Cash Flows From Finance Leases
OperatingCashFlowsFromFinanceLeases
|
20077 | |
| CY2022 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
70514 | |
| CY2021 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
61867 | |
| CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
717956 | |
| CY2021 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | |
| CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
16234 | |
| CY2021 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
25609 | |
| CY2022Q4 | cemi |
Finance Lease Right Of Use Asset Before Amortization
FinanceLeaseRightOfUseAssetBeforeAmortization
|
356997 | |
| CY2021Q4 | cemi |
Finance Lease Right Of Use Asset Before Amortization
FinanceLeaseRightOfUseAssetBeforeAmortization
|
340762 | |
| CY2022Q4 | cemi |
Finance Lease Right Of Use Asset Accumulated Depreciation
FinanceLeaseRightOfUseAssetAccumulatedDepreciation
|
220021 | |
| CY2021Q4 | cemi |
Finance Lease Right Of Use Asset Accumulated Depreciation
FinanceLeaseRightOfUseAssetAccumulatedDepreciation
|
148892 | |
| CY2022Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
136976 | |
| CY2021Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
191870 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
76869 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
68176 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
76705 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
139678 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
153574 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
207854 | |
| CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y7M6D | |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y6M | |
| CY2022Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y1M6D | |
| CY2021Q4 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y10M24D | |
| CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.087 | |
| CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0808 | |
| CY2022Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0918 | |
| CY2021Q4 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0876 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1428821 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
87884 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1447249 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
83624 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1220150 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
60116 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1221017 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
83624 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1049442 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
16731 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1018875 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
55856 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1080925 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
5940 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1049442 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
12471 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1113353 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
355 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1080925 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
1680 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
2530168 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
|
0 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
3643520 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
|
0 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
8422859 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
171026 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
9461028 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
237255 | |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2081972 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
17452 | |
| CY2021Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2598583 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
29401 | |
| CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
6340887 | |
| CY2022Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
153574 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
6862445 | |
| CY2021Q4 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
207854 | |
| CY2020 | us-gaap |
Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
|
4 | |
| CY2021Q1 | us-gaap |
Loss Contingency Number Of Plaintiffs
LossContingencyNumberOfPlaintiffs
|
15 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
943126 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
266666 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P30D | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P30D | |
| CY2022 | cemi |
Number Of Complaint Purpote To Allege Claims For Breach Of Each Separate Stock Option Agreements
NumberOfComplaintPurpoteToAllegeClaimsForBreachOfEachSeparateStockOptionAgreements
|
10 | |
| CY2022Q4 | cemi |
Percentage Of Prejudgment Interest Rate
PercentageOfPrejudgmentInterestRate
|
0.09 | |
| CY2022Q2 | cemi |
Minimum Bid Price Requirement Price Per Share For Listing
MinimumBidPriceRequirementPricePerShareForListing
|
1 | |
| CY2022 | cemi |
Minimum Bid Price Requirement Threshold Consecutive Business Days To Regain Compliance
MinimumBidPriceRequirementThresholdConsecutiveBusinessDaysToRegainCompliance
|
P180D | |
| CY2022 | cemi |
Minimum Bid Price Requirement Threshold Consecutive Business Days To Regain Compliance
MinimumBidPriceRequirementThresholdConsecutiveBusinessDaysToRegainCompliance
|
P180D | |
| CY2022Q2 | cemi |
Minimum Bid Price Requirement Price Per Share For Listing
MinimumBidPriceRequirementPricePerShareForListing
|
1 | |
| CY2022 | cemi |
Minimum Bid Price Requirement Threshold Consecutive Business Days To Regain Compliance
MinimumBidPriceRequirementThresholdConsecutiveBusinessDaysToRegainCompliance
|
P180D | |
| CY2022Q1 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
3000000 | |
| CY2022 | us-gaap |
Severance Costs1
SeveranceCosts1
|
200000 | |
| CY2021 | us-gaap |
Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
|
7000000 | |
| CY2021 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
5900000 | |
| CY2021 | us-gaap |
Restructuring Costs
RestructuringCosts
|
1100000 | |
| CY2021 | us-gaap |
Severance Costs1
SeveranceCosts1
|
100000 | |
| CY2022 | us-gaap |
Severance Costs1
SeveranceCosts1
|
202621 | |
| CY2021 | us-gaap |
Severance Costs1
SeveranceCosts1
|
83087 | |
| CY2022 | us-gaap |
Restructuring Costs
RestructuringCosts
|
0 | |
| CY2021 | us-gaap |
Restructuring Costs
RestructuringCosts
|
1083951 | |
| CY2022 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
3033565 | |
| CY2021 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
5880741 | |
| CY2022 | us-gaap |
Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
|
3236186 | |
| CY2021 | us-gaap |
Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
|
7047779 |
